dc.contributor.author
Paniskaki, Krystallenia
dc.contributor.author
Anft, Moritz
dc.contributor.author
Meister, Toni L.
dc.contributor.author
Marheinecke, Corinna
dc.contributor.author
Pfaender, Stephanie
dc.contributor.author
Skrzypczyk, Sarah
dc.contributor.author
Seibert, Felix S.
dc.contributor.author
Thieme, Constantin J.
dc.contributor.author
Konik, Margarethe J.
dc.contributor.author
Dolff, Sebastian
dc.contributor.author
Anastasiou, Olympia
dc.contributor.author
Holzer, Bodo
dc.contributor.author
Dittmer, Ulf
dc.contributor.author
Queren, Christine
dc.contributor.author
Fricke, Lutz
dc.contributor.author
Rohn, Hana
dc.contributor.author
Westhoff, Timm H.
dc.contributor.author
Witzke, Oliver
dc.contributor.author
Stervbo, Ulrik
dc.contributor.author
Roch, Toralf
dc.contributor.author
Babel, Nina
dc.date.accessioned
2022-08-31T11:47:39Z
dc.date.available
2022-08-31T11:47:39Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/36101
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-35817
dc.description.abstract
SARS-CoV-2 variants of concern (VOCs) can trigger severe endemic waves and vaccine breakthrough infections (VBI). We analyzed the cellular and humoral immune response in 8 patients infected with the alpha variant, resulting in moderate to fatal COVID-19 disease manifestation, after double mRNA-based anti-SARS-CoV-2 vaccination. In contrast to the uninfected vaccinated control cohort, the diseased individuals had no detectable high-avidity spike (S)-reactive CD4+ and CD8+ T cells against the alpha variant and wild type (WT) at disease onset, whereas a robust CD4+ T-cell response against the N- and M-proteins was generated. Furthermore, a delayed alpha S-reactive high-avidity CD4+ T-cell response was mounted during disease progression. Compared to the vaccinated control donors, these patients also had lower neutralizing antibody titers against the alpha variant at disease onset. The delayed development of alpha S-specific cellular and humoral immunity upon VBI indicates reduced immunogenicity against the S-protein of the alpha VOC, while there was a higher and earlier N- and M-reactive T-cell response. Our findings do not undermine the current vaccination strategies but underline a potential need for the inclusion of VBI patients in alternative vaccination strategies and additional antigenic targets in next-generation SARS-CoV-2 vaccines.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
breakthrough infection
en
dc.subject
neutralizing antibodies
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
816220
dcterms.bibliographicCitation.doi
10.3389/fimmu.2022.816220
dcterms.bibliographicCitation.journaltitle
Frontiers in Immunology
dcterms.bibliographicCitation.originalpublishername
Frontiers Media SA
dcterms.bibliographicCitation.volume
13
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35145522
dcterms.isPartOf.eissn
1664-3224